Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

Head and Neck Cancer

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial

JAMA Oncol

Guo SS, Li XY, Liu LT, Jia GD, Liu SL, Sun XS, Luo DH, Yang JH, Xie SY, Li YF, Lv X, Xiang YQ, Xia WX, Sun R, Liu Q, Li JB, Wang P, Yang Q, Wang L, Wen DX, Jin J, Lin JY, Mo HY, Guo L, Zhao C, Guo X, Chen QY, Tang LQ, Mai HQ

doi: 10.1001/jamaoncol.2025.1597

Lung, Respiratory and Thoracic Cancer

LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial

Clin Cancer Res

Armstrong AJ, Dietz H, Balli D, Geese WJ, Duan C, Hung YH, Ip V, Li G, Graf RP, Ready N

doi: 10.1158/1078-0432.CCR-25-0952

Central Nervous System Tumors

Early Palliative Care for Patients with Glioblastoma: A randomized phase lll clinical trial (EPCOG)

Neuro Oncol

Golla H, Nettekoven C, Hellmich M, Appelmann I, Bausewein C, Becker G, Boehlke C, Brumbarova T, Civello D, Clusmann H, Haberland B, Henrik Heiland D, Herrlinger U, Jaspers B, Joshi M, Mülller D, Müller W, Na CH, Neukirchen M, Radbruch L, Rapp M, Rolke R, Ruge M, Sabel M, Schnell O, Schwartz J, Thon N, Vatter H, Baumgarten LV, Voltz R, Goldbrunner R, EPCOG Study Group

doi: 10.1093/neuonc/noaf230

Gastrointestinal Cancer

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306

Eur J Cancer

Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V

doi: 10.1016/j.ejca.2025.115388

Gastrointestinal Cancer

Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

Lancet Oncol

Modest DP, Fakih M, Salvatore L, Esaki T, Lopez-Bravo DP, Taieb J, Karamouzis M, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Tran Q, Chan E, Chao J, Majer IM, Pietrantonio F

doi: 10.1016/S1470-2045(25)00352-3

Skin Cancer

Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

Ann Oncol

Ten Ham RMT, Rohaan MW, Egeler M, Menezes R, Holz Borch T, Kessels R, Jedema I, Nuijen B, Nijenhuis C, van de Poll-Franse LV, Geukes Foppen MH, Lindenberg M, Mansfield Noringriis I, Monberg TJ, Donia M, van Harten W, Svane IM, Haanen JBAG, Retèl VP

doi: 10.1016/j.annonc.2025.06.005

Central Nervous System Tumors

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma

J Clin Oncol

Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin VA

doi: 10.1200/JCO-25-01204

Genitourinary Cancer

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Ann Oncol

Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, Shah AY, Porta C, Suárez C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, Scheffold C, Askelson M, Panzica J, Zhang J, van Kooten Losio M, Choueiri TK

doi: 10.1016/j.annonc.2025.09.006

Gastrointestinal Cancer

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

JAMA Oncol

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA

doi: 10.1001/jamaoncol.2025.5144

Related content

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial

LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial

Early Palliative Care for Patients with Glioblastoma: A randomized phase lll clinical trial (EPCOG)

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306

Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial